CD73, His-Tag (Human) Recombinant
Recombinant human CD73 (also known as NT5E, 5'-nucleotidase), encompassing amino acids 27-547. This construct contains a C-terminal His tag (6xHis). The protein was affinity purified.
≥90%
≥20 pmol/min/µg
CD73, or cluster of differentiation 73, is an enzyme which hydrolyzes AMP to adenosine. Increased concentrations of adenosine in the microenvironment has an immunosuppressive effect and promotes tumor cell growth.
Adenosine can enhance tumor growth via two mechanisms – 1) binding of adenosine to A2A and A2B receptors expressed on tumor cells directly promotes tumor cell proliferation and 2) binding of adenosine to A2A and A2B receptors on immune cells such as also inhibits the activity of pro-inflammatory, anti-tumor immune cells like CD4+ T Cells, CTLs, dendritic cells, NK cells, while and activating immunosuppressant cells like Tregs, MDSCs and TAMs.
Development of inhibitory antibodies and small molecules against CD73 could serve as a new therapeutic strategy in the treatment of cancer. In preclinical models have provided proof of concept for this hypothesis as Inhibition of CD73 in mouse models has resulted in anti-tumor effects, providing proof of concept for this hypothesis.
1. Deaglio, S. et al., J. Exp. Med. 2007; 204(6): 1257-1265.
2. Thompson, L.F., et al., J. Exp. Med. 2004; 200(11): 1395-1405.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.